Vidaza er indiceret til behandling af voksne patienter, som ikke er egnede til hæmatopoietisk stamcelletransplantation, og som lider af: • intermediær- 2 og højrisiko myelodysplastiske syndromer (MDS) i henhold til International Prognostic Scoring System (IPSS), • kronisk myelomonocytleukæmi (CMML) med 10- 29% blaster i marv uden myeloproliferativ sygdom, • akut myeloid leukæmi (AML) med 20- 30% blaster og multilinie dysplasi i henhold til klassifikationen fra World Health Organisation (WHO).
Vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with: • intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS), • chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder, • acute myeloid leukaemia (AML) with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification.